🔎 Trials Near Me

Hjem › Kronisk lymfatisk leukemi › Tennessee

Kliniske studier for Kronisk lymfatisk leukemi i Tennessee

17 studier for Kronisk lymfatisk leukemi søker deltakere på steder i Tennessee.

Byer i Tennessee

Offisiell studietekst (engelsk)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
  • Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RekruttererFase 3
Alder 65 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07321652

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
  • Ballad Health Cancer Care - Kingsport, Kingsport
  • Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga, Chattanooga
  • Tennessee Oncology, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Tennesse Oncology Chattanooga Downtown, Chattanooga
  • Tennessee Oncology, Pllc Nashville, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05006716

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • Tennessee Oncology, Pllc Nashville, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06973187

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  • Tennessee Oncology-Chattanooga ( Site 0045), Chattanooga
  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06136559

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07221500

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

  • SCRI Oncology Partners, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 31. aug. 2026 · NCT07516093

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

  • SCRI Oncology Partners, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07520006

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • Sarah Cannon Research Institute SCRI, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05254743

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • TriStar BMT, Nashville
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • The West Clinic, PLLC dba West Cancer Center, Germantown
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 19. mai 2026 · NCT06588478

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Baptist Clinical Research Institute, Memphis
RekruttererFase 1/2
Alder 12 til 95 · Alle kjønn · Oppdatert 15. apr. 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. mar. 2026 · NCT04830137

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • Tennessee Oncology, Nashville
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • Tennessee Oncology, Nashville
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876649

HPC Offered for PRESERVE Expansion

  • Tristar Centennial Medical Center, Nashville
RekruttererObservasjonsstudie
Alder 12 til 80 · Alle kjønn · Oppdatert 28. aug. 2025 · NCT07145411

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.